Pfizer and Celltrion win cell-culture spat

Pfizer’s Hospira and its biosimilar development partner Celltrion have won a summary judgement from a Massachusetts district court affirming that the cell-culture media they use to produce the Inflectra/Remsima (infliximab-dyyb) biosimilar does not infringe Janssen’s US patent 7,598,083 under the doctrine of equivalents.  

Pfizer’s Hospira and its biosimilar development partner Celltrion have won a summary judgement from a Massachusetts district court affirming that the cell-culture media they use to produce the Inflectra/Remsima (infliximab-dyyb) biosimilar does not infringe Janssen’s US patent 7,598,083 under the doctrine of equivalents.

Having seen its US infliximab antibody patent 6,284,471 invalidated for obvious-type double patenting by the Massachusetts court in 2016 –...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Archive

More from Generics Bulletin